Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,481
  • Shares Outstanding, K 27,605
  • Annual Sales, $ 84,510 K
  • Annual Income, $ -60,640 K
  • EBIT $ -109 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.70
  • Price/Sales 0.57
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 467.67% ( +138.99%)
  • Historical Volatility 84.42%
  • IV Percentile 99%
  • IV Rank 88.78%
  • IV High 523.16% on 11/15/24
  • IV Low 28.61% on 07/17/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 16
  • Volume Avg (30-Day) 210
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 7,094
  • Open Int (30-Day) 6,195

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.79
  • Number of Estimates 2
  • High Estimate -0.75
  • Low Estimate -0.83
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -49.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5500 +10.97%
on 11/22/24
2.3428 -26.58%
on 12/02/24
+0.1500 (+9.55%)
since 11/20/24
3-Month
1.3550 +26.94%
on 09/24/24
2.3428 -26.58%
on 12/02/24
+0.2250 (+15.05%)
since 09/20/24
52-Week
1.3550 +26.94%
on 09/24/24
4.4300 -61.17%
on 12/28/23
-0.6400 (-27.12%)
since 12/20/23

Most Recent Stories

More News
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

FBIO : 1.7200 (-1.15%)
CKPT : 3.75 (+11.28%)
Fortress Biotech Announces FDA Approval of Emrosi for Rosacea Treatment and Details Upcoming PDUFA for Cosibelimab

Fortress Biotech announced FDA approval for Emrosi for rosacea and a PDUFA date for cosibelimab. Financial results show a net loss.Quiver AI SummaryFortress Biotech, Inc. announced that its product Emrosi,...

FBIO : 1.7200 (-1.15%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 1.7200 (-1.15%)
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO : 1.7200 (-1.15%)
FBIOP : 6.61 (-2.15%)
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FBIO : 1.7200 (-1.15%)
CKPT : 3.75 (+11.28%)
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Journey Medical Corporation Announces U.S. FDA Approval of Emrosiâ„¢ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

FBIO : 1.7200 (-1.15%)
ATXI : 1.7700 (-1.67%)
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 1.8700
2nd Resistance Point 1.8400
1st Resistance Point 1.7800
Last Price 1.7200
1st Support Level 1.6900
2nd Support Level 1.6600
3rd Support Level 1.6000

See More

52-Week High 4.4300
Fibonacci 61.8% 3.2553
Fibonacci 50% 2.8925
Fibonacci 38.2% 2.5296
Last Price 1.7200
52-Week Low 1.3550

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar